Guardian Pharmacy price target raised to $30 from $28 at Truist

Truist analyst David MacDonald raised the firm’s price target on Guardian Pharmacy (GRDN) to $30 from $28 and keeps a Buy rating on the shares. The firm remain bullish on Guardian post management meetings highlighting the company’s strong positioning in a market with brisk core demand, overarching tailwinds and ongoing expansion opportunity, the analyst tells investors in a research note. Truist adds that Guardian’s core trends remain strong, and the firm sees an attractive earnings power opportunity from recently acquired facilities.